Sleep changes across the adult life course and, in recent years, disturbed sleep has been linked with several diseases common in older adults, including neurodegenerative disease and dementia. Here, we review changes in sleep related to aging, sleep disturbances in persons with cognitive impairment and dementia in general (i.e., all-cause dementia) and with particular dementias-namely Alzheimer's disease (AD) and Parkinson's disease (PD). We also summarize findings from studies in the general population of older adults linking sleep disturbances to cognitive performance, decline, and dementia, and to the pathology underlying particular dementias. We close with a brief discussion of strategies for diagnosing and treating sleep problems in persons with dementia. Although there are still gaps in the
Sleep and All-Cause Cognitive Decline and Dementia
Disturbances of sleep and wake are especially common among people with dementia. As many as 70% of patients in earlystage dementia have sleep disturbances. 11 Sleep disturbance in people with dementia is predictive of poorer outcomes, including more severe cognitive and neuropsychiatric symptoms, and poorer quality of life. [11] [12] [13] [14] [15] [16] [17] [18] Among institutionalized dementia patients, sleep-wake cycles can be so disrupted that they are neither continuously awake or asleep for a full hour during a 24-hour period. 19 Even among older women without dementia, declining cognition is associated with poorer objectively measured sleep quality at follow-up.
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In addition to being prevalent in persons with dementia, poor sleep and altered circadian rhythms are common in healthier older populations. Moreover, these disturbances are associated with an increased risk of adverse cognitive outcomes, suggesting a possible causal link from disturbed sleep to cognitive decline. Furthermore, short sleep duration, 21 Overall, there appears to be a U-shaped association between sleep duration and cognitive impairment, whereby both short and long sleep are associated with poorer cognition. 32 Various mechanisms have been proposed to explain how short or insufficient sleep could lead to cognitive impairment and decline (see below), but it is unclear which physiological or biological mechanisms may be linking longer sleep duration to dementia risk. Longer sleep duration may be an early marker of dementia, with a confounder (e.g., apnea, depression) driving both development of cognitive impairment and an increased sleep need. 33 Importantly, both sleep duration and sleep quality in midlife have been linked to poorer cognitive function in later life, 34 although we do not currently know how the timing of poor sleep in the life course differentially affects cognitive outcomes. Sleep disordered breathing (SDB), including obstructive sleep apnea (OSA), is among the most common clinical sleep disorders, affecting 60% of older adults, with higher rates among men. [35] [36] [37] [38] [39] An estimated 70 to 80% of people with dementia may have sleep apnea, and SDB severity increases with dementia severity, raising the possibility of a positivefeedback loop in which dementing illnesses exacerbate SDB, and vice versa. 40 Obstructive sleep apnea is also linked with poorer attention, executive functioning, visuospatial and constructional abilities, and psychomotor speed in nondemented persons. [41] [42] [43] In prospective longitudinal studies,
OSA has been associated with a 2 to 6 times greater risk of mild cognitive impairment (MCI) or dementia, 44, 45 and earlier onset of MCI or dementia. 46 Moreover, subjectively measured excessive daytime sleepiness, a common symptom of SDB, has been associated with subsequent cognitive decline, 47 perhaps suggesting that complaints about sleep quality are an early marker of cognitive decline. The association of sleep quality, quantity, and sleep-disordered breathing with all-cause cognitive impairment may be mediated by a range of processes. For example, sleep disturbances have been linked to cortical thinning, a marker of cortical atrophy found in many dementia subtypes. 48, 49 In a cross-sectional study of 141 cognitively normal communitydwelling older adults (median age ¼ 82.9 years), decreased cortical thickness in the lateral orbitofrontal cortex and inferior frontal gyrus was associated with increased sleep fragmentation as measured by an Actigraph (a wrist-worn device that records movement over several days that uses a 53 Shorter sleep duration may also contribute to cognitive decline via degeneration of the hippocampus through multiple pathways, including changes in neuronal excitability, decreasing synaptic plasticity, and decreasing neurogenesis.
54,55
Similarly, sleep apnea has been associated with multiple brain changes, including magnetic resonance imaging (MRI) and diffusion tensor imaging (DTI) measures of loss of regional volume and white matter integrity in the hippocampus, cingulate cortex, and some cerebellar regions. 
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In summary, sleep disruption, sleep duration, and sleep disorders-specifically SDB-all may increase the risk of allcause cognitive decline and dementia. Conversely, populations with clinical levels of cognitive decline, including AD, exhibit an elevated rate of sleep disturbances. A bidirectional link appears to exist between disturbed sleep and dementia.
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Disturbed Sleep and Dementia Subtypes
In addition to the associations with all-cause cognitive decline and dementia described above, poor sleep and sleep disorders (e.g., insomnia, SDB, REM sleep behavior disorder [RBD]) have been identified in relation to particular dementia subtypes. Here, we review two: AD-and PD-related dementias.
Alzheimer's Disease
Alzheimer's disease is the most common cause of dementia, accounting for 80% of all cases. Conversely, disturbed sleep parameters have also been linked to an increased risk of subsequently developing AD. Self-report of shorter sleep duration ( 5 hours) is associated with 2.4 times the odds of AD, and self-reported longer sleep duration ( 9 hours) is associated with 2.8 times the odds of AD. 75 Further, in a community-based sample, greater actigraphic-measured sleep fragmentation was associated with a greater risk of incident AD over approximately 3 years, and that those with the most sleep fragmentation had a 50% greater risk of developing AD compared with those with the least fragmentation. 76 Additionally, it was found that more consolidated (i.e., less fragmented) sleep decreased the elevated risk of developing AD attributable to the APOE ε4 allele over an average of 3 years. 77 Insomnia symptoms have also been associated with an increased risk of MCI or AD, with rates ranging from approximately 2 to 3 times above older adults without insomnia.
78,79
Although these studies show altered sleep duration, sleep fragmentation, and insomnia precede MCI or AD diagnosis, these sleep disturbances may be an early marker of cognitive impairment, especially because AD pathology can develop decades prior to diagnosis. 70 These findings suggest that disturbed sleep may causally promote development of AD or may be an early marker of the disease. Importantly, they also suggest that good sleep may protect against AD. Some of the associations between sleep and dementia discussed above in the Sleep and All-Cause Cognitive Decline and Dementia section may be explained by studies that show mechanistic links between sleep and AD-related pathology. For instance, sleep disturbances have been robustly associated with Aβ dynamics and deposition. In a study by Kang et al, levels of Aβ in brain interstitial fluid (ISF) were positively correlated with the amount of time spent awake, but negatively correlated with the amount of time spent asleep in a transgenic mouse model of AD; moreover, humans exhibited a similar fluctuation of cerebrospinal fluid (CSF) Aβ levels.
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Attenuated Aβ diurnal patterns were also observed in the CSF of young adult human participants with presenilin mutations. 81 The connection between sleep and Aβ has also been supported by community-based cohort studies showing that both self-reported and objectively measured sleep disturbances are associated with greater cerebral Aβ deposition, as measured by [
11 C] -Pittsburgh compound B-positron emission tomography (PiB-PET) 82 and lower CSF Aβ levels (which is generally associated with greater brain burden of Aβ
83
), respectively. 68 Findings from Drosophila models show sleep deprivation causes excessive neuronal excitability, which results in greater Aβ accumulation, 84 implicating neuronal excitability in the pathogenesis of AD.
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Alternatively, it has been suggested that the association between sleep and Aβ is driven by dysfunction of the recently discovered "glymphatic system." The glymphatic system is a macroscopic waste clearance system that functions through the exchange of CSF and ISF through channels formed by Additionally, people with AD have been shown to have greater SCN degeneration on autopsy compared with cognitively intact elderly, supporting the notion that disrupted circadian rhythms are the result of SCN degeneration in AD.
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Relatedly, among people with AD, greater actigraphically measured sleep fragmentation has been associated with a decreased number of galanin-immunoreactive neurons in the VLPO on autopsy. 97 Although it remains unclear whether circadian rhythms are disrupted due to neurodegeneration of the SCN and/or VLPO or due to disrupted processing of endogenous cues (e.g., limited bright light exposure), circadian rhythm disruption has a negative impact on sleep and function in people with AD and may put cognitively normal people at risk for developing dementia.
98
Finally, the high prevalence of OSA among people with AD 99 and evidence linking OSA with Alzheimer's pathology suggests that OSA may affect core AD mechanisms. Indeed, the strength of the association and mechanistic links between OSA and AD has even caused some researchers to identify OSA as a prodromal stage of AD. 100 Specifically, hypoxia has been associated with AD pathology. In cellular and murine models, chronic hypoxia increases Aβ plaque formation, 101 and acute hypoxia has been shown to increase tau phosphorylation. 102 In cognitively normal adults, OSA has been associated with lower CSF levels of Aβ and tau; 103 however, others have shown that this association was significant only among those with the APOE ε3 allele.
104
Further, a pilot study that measured cerebral Aβ deposition using PiB-PET imaging found that SDB was associated with greater Aβ burden only among participants with MCI.
105
More research, particularly prospective research, is needed to better understand the association between SDB and AD-associated pathology. 
117-122
One recent longitudinal study among 421 people with PD found that, over an average of 4.6 years, insomnia was more common with longer duration of PD and in women. 123 Further, depressive symptoms and dopamine agonists were risk factors for developing insomnia; motor symptoms and sleep medication use were associated with more severe insomnia. Because in PD sleep problems may perpetuate other PD symptoms and vice versa, identifying and addressing sleep disturbances can be critical for patient quality of life and, potentially, prognosis. Perhaps unsurprisingly, motor-related sleep disorders are among the most common frank disorders in PD. For instance, restless leg syndrome (RLS) is prevalent among 15% of people with PD. 115 In untreated PD, RLS prevalence rates are similar to those in the general population; however, due to augmentation of RLS symptoms by PD medications, prevalence rates are higher in treated PD, with some studies suggesting nearly a fourfold increase. 124 It has been hypothesized that dopamine agonist treatment is associated with RLS through overstimulation of dopamine receptors. 125 Sleep disordered breathing is also common in PD patients, with prevalence estimates ranging from 20% to nearly 70%. 126 People with PD and OSA have been shown to have poorer cognitive function than people with PD without OSA. 127 Findings that OSA is common in PD are not unexpected given that upper airway and pulmonary obstruction are often observed in PD.
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Rapid eye movement sleep behavioral disorder is strongly associated with PD and dementia with DLBs. People with RBD have impaired skeletal muscle atonia, resulting in significant motor activity (i.e., acting out violent dreams) during REM sleep. 130, 131 Epidemiological studies on RBD prevalence are lacking, but current estimates suggest prevalence is 0.5%. Notably, RBD is also commonly diagnosed after the onset of PD, and is prevalent in both early and later stages of PD.
140,141
Though the mechanisms linking RBD and DLB have not yet been fully elucidated, patients with RBD without dementia should be monitored for signs of DLBs and PD-related disorders.
130,142
Further details about RBD are available in reviews from Jennum and colleagues 142 and Boeve.
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Beyond the proposed mechanistic link between RBD and DLBs, other pathological facets of PD are implicated in sleep disturbances. Alpha-synuclein aggregation, in addition to its role in RBD, may decrease neuronal firing in the SCN, reducing its ability to regulate circadian rhythms and thereby affecting sleep. 143 Further, degeneration of the hypothalamus is also observed in PD, 144 and may disrupt SCN functionality and decrease melatonin production, 145, 146 which is more disrupted in PD patients with excessive daytime sleepiness. 147 Multiple areas affecting sleep-wake regulation (e.g., cholinergic pedunculopontine nucleus, serotonergic tegmental area, nucleus magnocellularis, and noradrenergic locus coeruleus) are also deteriorated in PD and may also contribute to sleep problems. 148, 149 Finally, dopamine is key for maintaining wakefulness and regulating sleep homeostasis, 150 and mediates circadian signals via the SCN. 151, 152 Therefore, the characteristic decline in dopaminergic neurotransmission in PD is thought to be a cause of many sleep problems associated with the disease.
Assessment and Treatment of Sleep Disorders in Dementia
Diagnosing sleep problems in people with dementia can be difficult due to impaired memory and lack of insight.
69,153
Therefore, it is important to interview both patients and caregivers. 154 During these interviews, bed and wake times and bedtime routines should be reviewed. It should also be noted that sleep problems in people with dementia are associated with burden in caregivers of persons with dementia, in particular spousal caregivers. 11, 155 Indeed, sleep disruption in dementia patients relating to caregiver burden has been found to be a primary reason for placing people with dementia in nursing homes, 155,156 so identifying and treating sleep disruption in dementia can be crucial to the well-being of patients and caregivers. We have summarized our recommendations in ►Table 1 and for more details, see a recent extensive review by Ooms and Ju.
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Treating Insomnia
Although both pharmacological and nonpharmacological interventions are widely used in clinical practice to treat insomnia in dementia, there are few rigorous clinical trials to inform clinicians' choices. The most important consideration in pharmacological interventions is to balance the considerable risks of psychotropic medications in demented patients. For example, many of the Food and Drug Administrationapproved medications for insomnia are benzodiazepines. These drugs have many risks for adverse effects in dementia, including addiction, gait instability, worsening cognition, and drug-drug interactions, and their use is generally discouraged. A newer class of related drugs (zaleplon, zolpidem, and zopiclone) has not been studied in dementias, nor has the orexin antagonist suvorexant. The most commonly used drug for insomnia is AD is trazodone, an older antidepressant that may improve sleep onset at low doses through its sedative effect. Adverse effects from trazodone (including priapism, sedation, and orthostatic hypotension) are not common at low doses (25-50 mg) in demented patients, and there is no apparent risk of addiction. Trazodone may improve circadian cycle and sleep parameters in AD, and given its benign adverse event profile it is widely used.
158,159
There is evidence for sleep improvement in AD with the use of the second-generation antipsychotic risperidone. However, the use of antipsychotics in AD is quite controversial due to increased mortality risk, and their use is necessarily limited. 163, 164 Another medication is the antidepressant mirtazapine, which has been reported to benefit sleep in AD as a secondary outcome of an randomized controlled trial targeting depression.
160-162
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The agent melatonin is available over-the-counter and noted to have minimal adverse events in older adults. A recent meta-analysis of randomized controlled trials of melatonin use in people with dementia found that, compared with placebo, melatonin improved SE, TST, and global cognitive performance, and that very few adverse events occurred. 166 However, others have reported null effects, 167,168 perhaps due to the significant reduction of melatonin receptors in the SCN among people with dementia. 169 It should be noted that exogenous melatonin is a chronobiotic agent that alters circadian phase, and not a pharmaceutical developed specifically for the treatment of insomnia.
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Although many nonpharmacological treatments for insomnia in dementia have been investigated, bright-light therapy may be especially important because older adults with dementia have very little bright light exposure.
171 Lack of bright light exposure negatively impacts sleep and circadian rhythms, and is linked with other negative outcomes (e.g., poorer cognition, neuropsychiatric symptoms).
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People with dementia who have insomnia or insomnia symptoms may also benefit from reducing or eliminating caffeine and alcohol consumption, refraining from drinking near bedtime (to avoid or reduce nighttime trips to the bathroom), maintaining a dark and quiet bedroom, and avoiding napping during the day. 153, 173 Physical activity regimens have also been shown to improve sleep in people with dementia-causing diseases. 174, 175 Among persons with PD, deep brain stimulation, a common treatment for motor symptoms in PD, has also been shown to improve subjective and objective sleep quality, RLS, and SDB. 176 These findings suggest nonpharmacological approaches are effective and safe, with few studies reporting adverse events; therefore, they should be considered for management of both daytime and nighttime disturbances.
Treating Daytime Sleepiness
Similar to treatment for insomnia, melatonin has also been shown to improve daytime sleepiness and increase daytime activity. [177] [178] [179] [180] Daytime sleepiness may also be alleviated by changing medication type and dosing. 154 Daytime sleepiness is common among people with dementia and is a particular problem in PD. A recent meta-analysis found that physical activity may improve daytime sleepiness, as well as several other symptoms (e.g., depression and cognition) thought to be associated with sleep disturbance in PD. 174 Evidence from studies investigating the impact of pharmacological treatments suggests that modafinil, and to a lesser extent caffeine and atomoxetine, can improve excessive daytime sleepiness in PD. 181 Overall, daytime sleepiness and nighttime sleep problems are often cyclically linked, with one problem exacerbating the other, so strategies aimed at addressing either problem may help alleviate the other as well. 
Treating Sleep Disordered Breathing in Dementia
Treating REM Sleep Behavior Disorder
The most common and effective treatments for RBD include melatonin and/or clonazepam. [188] [189] [190] [191] However, clonazepam may cause side effects (e.g., sedation, memory impairment, confusion), and should be used with caution, particularly in patients with cognitive impairment or OSA. 192 It is also important to remove potentially injurious objects from the bedroom, set alarms to be alerted if the patient opens a door or window, and create barriers to keep patients and their bed partners safe. People with RBD should consider avoiding substances and medications (e.g., some antidepressants, caffeine, and chocolate) that may exacerbate the condition. In particular, selective serotonin reuptake inhibitors and selective norepinephrine reuptake inhibitors have been shown to cause or exacerbate RBD in some patients. 193, 194 Further details on RBD management strategies are available elsewhere.
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Limitations and Suggestions for Future Directions
Although the field of research investigating the links between sleep and dementia has grown substantially in the past 20 years, future studies are needed to further probe these relationships. First, there is a paucity of longitudinal evidence examining the association between sleep and dementia. In this review, of the studies conducted in humans assessing risk factors or potential therapies for sleep disorders, fewer than half of the studies had a longitudinal design. Therefore, it is difficult to make conclusions about the potential for disturbed sleep to cause or promote dementia pathology or vice versa-though likely both are true. Future studies with prospective longitudinal designs should investigate (1) how sleep impacts risk of incident dementia of specific subtypes, (2) how co-occurring sleep problems and dementia impact trajectories of sleep and dementia, and (3) whether treating sleep problems reduces dementia risk. Recent research has begun to focus on the pathophysiological links between sleep and dementia (e.g., Mander et al, 2016 91 ). These studies are crucial for understanding both the etiological contribution that sleep makes in the development of dementia, as well as how sleep disturbance may be a prognostic marker for trajectories of cognitive impairment and dementia. Additional studies focusing on the pathophysiology and biomarkers linking sleep and clinical dementia will be important for enhancing both our understanding of the association and potential interventions for sleep disorders and dementia. Furthermore, few studies have investigated the association between sleep and frontotemporal dementia (FTD) or vascular dementia (VaD). Frontotemporal dementia affects 0.02% of the population, 195 and the few studies that have been conducted suggest that people with FTD exhibit a phase delay and decreased TST and SE.
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Vascular dementia is the second most common cause of dementia, affecting 10 to 15% of adults over 65. 197,198 Vascular dementia and AD pathology often present together, 199 suggesting that any links between sleep and AD may also be pertinent to persons with clinically diagnosed VaD. Additionally, white matter hyperintensities, a pathological hallmark of VaD, have been associated with disrupted circadian rhythms. 200 Finally, some studies have found that after adjusting for depressive symptoms, there is no longer an association between sleep and cognition. 201 Therefore, it is also important for studies to consider potential confounders in the association between sleep and dementia. In particular, depression, polypharmacy, and undiagnosed comorbid medical conditions may drive observed associations between sleep and dementia and have important implications for treatment and perhaps prevention.
Conclusion
The association between sleep and dementia is complex and likely bidirectional. There are multiple ways in which sleep and dementia are linked. Brain pathology underlying dementia may lead to disturbed sleep, sleep disturbance may contribute to the development of dementia, and co-occurring sleep disturbances and dementia may lead to a more rapid decline. The majority of the research that has been conducted has been cross-sectional and has focused on sleep as a risk factor for and within the context of AD. 78, 79, [202] [203] [204] Identifying and treating disturbed sleep in persons with dementia may ameliorate multiple outcomes, including dementia course and caregiver burden. 155, 156 Because sleep is a modifiable behavior, it is also an important potential target for intervention on cognitive decline and dementia. Disturbed sleep as early as in middleage may increase the risk of dementia; this could have significant implications for AD prevention. Indeed, sleep may have to be targeted in midlife, like other AD risk factors (e.g., type II diabetes mellitus), to prevent AD. However, more research in this area is needed. Moving forward, sleep research has the potential to determine trajectories of dementia, improve patient prognosis, and reduce the risk of poor clinical outcomes, including dementia itself.
